Drug discovery for Chagas disease should consider Trypanosoma cruzi strain diversity
Mem. Inst. Oswaldo Cruz
; 109(6): 828-833, 09/09/2014. tab, graf
Article
em En
| LILACS
| ID: lil-723996
Biblioteca responsável:
BR1.1
ABSTRACT
This opinion piece presents an approach to standardisation of an important aspect of Chagas disease drug discovery and development selecting Trypanosoma cruzi strains for in vitro screening. We discuss the rationale for strain selection representing T. cruzi diversity and provide recommendations on the preferred parasite stage for drug discovery, T. cruzi discrete typing units to include in the panel of strains and the number of strains/clones for primary screens and lead compounds. We also consider experimental approaches for in vitro drug assays. The Figure illustrates the current Chagas disease drug-discovery and development landscape.
Palavras-chave
Texto completo:
1
Base de dados:
LILACS
Assunto principal:
Tripanossomicidas
/
Trypanosoma cruzi
/
Doença de Chagas
/
Descoberta de Drogas
Tipo de estudo:
Guideline
Idioma:
En
Revista:
Mem. Inst. Oswaldo Cruz
Assunto da revista:
MEDICINA TROPICAL
/
PARASITOLOGIA
Ano de publicação:
2014
Tipo de documento:
Article
País de afiliação:
Brasil